{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:18:50Z","timestamp":1790691530190,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T00:00:00Z","timestamp":1467590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81472029"],"award-info":[{"award-number":["No.81472029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"National Natural Science Foundation of Beijing","doi-asserted-by":"crossref","award":["No.7162155"],"award-info":[{"award-number":["No.7162155"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00277-016-2712-0","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T08:50:14Z","timestamp":1467622214000},"page":"1391-1398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis"],"prefix":"10.1007","volume":"95","author":[{"given":"Yu-Qing","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,4]]},"reference":[{"key":"2712_CR1","volume-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES et al (2008) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon"},{"issue":"9","key":"2712_CR2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.23703","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A (2014) Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(9):915\u2013925","journal-title":"Am J Hematol"},{"issue":"4","key":"2712_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","volume":"158","author":"JT Reilly","year":"2012","unstructured":"Reilly JT, McMullin MF, Beer PA et al (2012) Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 158(4):453\u2013471","journal-title":"Br J Haematol"},{"issue":"17","key":"2712_CR4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779\u20131790","journal-title":"N Engl J Med"},{"issue":"9464","key":"2712_CR5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054\u20131061","journal-title":"Lancet"},{"issue":"4","key":"2712_CR6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387\u2013397","journal-title":"Cancer Cell"},{"issue":"25","key":"2712_CR7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405","journal-title":"N Engl J Med"},{"issue":"25","key":"2712_CR8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390","journal-title":"N Engl J Med"},{"issue":"2","key":"2712_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-014-1724-6","volume":"101","author":"Y Yang","year":"2015","unstructured":"Yang Y, Wang X, Wang C et al (2015) A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia. Int J Hematol 101(2):165\u2013172","journal-title":"Int J Hematol"},{"key":"2712_CR10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"issue":"4","key":"2712_CR11","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719\u2013748","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2712_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"7414","key":"2712_CR13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"7109","key":"2712_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"15","key":"2712_CR15","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Tischer A et al (2014) The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 124(15):2465\u20132466","journal-title":"Blood"},{"issue":"7","key":"2712_CR16","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke C et al (2014) Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 28(7):1568\u20131570","journal-title":"Leukemia"},{"issue":"7","key":"2712_CR17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472\u20131477","journal-title":"Leukemia"},{"issue":"7","key":"2712_CR18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3346\/jkms.2015.30.7.882","volume":"30","author":"BH Kim","year":"2015","unstructured":"Kim BH, Cho YU, Bae MH et al (2015) JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. J Korean Med Sci 30(7):882\u2013888","journal-title":"J Korean Med Sci"},{"issue":"10","key":"2712_CR19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1179\/1607845415Y.0000000018","volume":"20","author":"S Sazawal","year":"2015","unstructured":"Sazawal S, Singh N, Mahapatra M et al (2015) Calreticulin mutation profile in Indian patients with primary myelofibrosis. Hematology 20(10):567\u2013570","journal-title":"Hematology"},{"issue":"5","key":"2712_CR20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","volume":"143","author":"SY Kim","year":"2015","unstructured":"Kim SY, Im K, Park SN et al (2015) CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol 143(5):635\u2013644","journal-title":"Am J Clin Pathol"},{"issue":"16","key":"2712_CR21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507\u20132513, quiz 2615","journal-title":"Blood"},{"issue":"10","key":"2712_CR22","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2014.109199","volume":"99","author":"C Qiao","year":"2014","unstructured":"Qiao C, Sun C, Ouyang Y et al (2014) Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica 99(10):e182\u2013e184","journal-title":"Haematologica"},{"issue":"11","key":"2712_CR23","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3324\/haematol.2014.109249","volume":"99","author":"B Li","year":"2014","unstructured":"Li B, Xu J, Wang J et al (2014) Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica 99(11):1697\u20131700","journal-title":"Haematologica"},{"issue":"7","key":"2712_CR24","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C et al (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124(7):1062\u20131069","journal-title":"Blood"},{"issue":"7","key":"2712_CR25","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","volume":"99","author":"H Andrikovics","year":"2014","unstructured":"Andrikovics H, Krahling T, Balassa K et al (2014) Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica 99(7):1184\u20131190","journal-title":"Haematologica"},{"issue":"2","key":"2712_CR26","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3324\/haematol.2014.115113","volume":"100","author":"S Shirane","year":"2015","unstructured":"Shirane S, Araki M, Morishita S et al (2015) JAK2, CALR, and MPL mutation spectrum in japanese patients with myeloproliferative neoplasms. Haematologica 100(2):e46\u2013e48","journal-title":"Haematologica"},{"issue":"10","key":"2712_CR27","doi-asserted-by":"crossref","first-page":"e360Q","DOI":"10.1038\/bcj.2015.90","volume":"5","author":"P Guglielmelli","year":"2015","unstructured":"Guglielmelli P, Rotunno G, Fanelli T et al (2015) Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 5(10):e360Q","journal-title":"Blood Cancer J"},{"issue":"13","key":"2712_CR28","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901","journal-title":"Blood"},{"issue":"9","key":"2712_CR29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703\u20131708","journal-title":"Blood"},{"issue":"5","key":"2712_CR30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajh.23678","volume":"89","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Nangalia J, Green AR et al (2014) CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol 89(5):453\u2013456","journal-title":"Am J Hematol"},{"issue":"3","key":"2712_CR31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3109\/10428194.2014.939963","volume":"56","author":"HJ Shen","year":"2015","unstructured":"Shen HJ, Chao HY, Ding ZX et al (2015) CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. Leuk Lymphoma 56(3):820\u2013822","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2712_CR32","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","volume":"100","author":"C Al Assaf","year":"2015","unstructured":"Al Assaf C, Van Obbergh F, Billiet J et al (2015) Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 100(7):893\u2013897","journal-title":"Haematologica"},{"issue":"10","key":"2712_CR33","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544\u20131551","journal-title":"Blood"},{"issue":"9","key":"2712_CR34","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/leu.2014.138","volume":"28","author":"R Fu","year":"2014","unstructured":"Fu R, Xuan M, Zhou Y et al (2014) Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia 28(9):1912\u20131914","journal-title":"Leukemia"},{"issue":"8","key":"2712_CR35","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P et al (2014) Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121\u2013E124","journal-title":"Am J Hematol"},{"issue":"9","key":"2712_CR36","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P et al (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861\u20131869","journal-title":"Leukemia"},{"issue":"9","key":"2712_CR37","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G et al (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28(9):1804\u20131810","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2712-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2712-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2712-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:42:04Z","timestamp":1589676124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2712-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,4]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2712-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,4]]}}}